There are always new treatments for Parkinson’s disease on the horizon and with so many minds working on this, developments are inevitable. A particular drug, dipraglurant, has shown promising results when tested for the treatment of levodopa-induced dyskinesia (PD-LID). The approach is to block a specific glutamate receptor that has previously been linked to excess glutamate activity in those with Parkinson’s disease. A recent trial of 72 patients studied aspects such as safety and the results were reportedly positive. According to a recent press release, “dipraglurant appears to reduce dystonia severity in addition to chorea, the two major LID components.”

Since no drug has yet been approved by the FDA to treat dyskinesia, progress here is welcomed. For more details, see a summary at Addex Therapeutics.